Biocon Biologics - Biosimilars Business in the Capital Markets

Biocon biologics is looking to hit the capital markets by an initial public offering, or, i po in the next 18 to 24 months. There are some marky investors, i think, including goldman sack and true north, and even a terem institute have envested in this biogon bologic. So there is already a lot of expectations that are inwhen these companies have taken so much of a position in a future potential of a company.